Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).

Sun A YoonByoung G HanSung G KimSang Y HanYoung I JoKyung H JeongKook H OhHyeong C ParkSun H ParkShin W KangKi R NaSun W KangNam H KimYoung H JangSeong H ShinDae Ryong Cha

Published in: Diabetes, obesity & metabolism (2017)

A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.

Keyphrases

type diabetes
body weight
placebo controlled
glycemic control
double blind
high intensity
early onset
clinical trial
cardiovascular disease
insulin resistance
drug induced
randomized controlled trial
metabolic syndrome
phase ii
weight loss
skeletal muscle